

Prognostic Significance of Serum Beta-2 Microglobulin in Patients with HIV Infection and AIDS

Shiraz Mujtaba and Shobha Sehgal

Department of Immunopathology, Postgraduate Institute of Medical Education and Research, Chandigarh 160 012.

SUMMARY

Evaluation of beta-2 microglobulin [b₂M] levels was undertaken in 34 cases of full blown acquired immunodeficiency syndrome [AIDS], 20 apparently healthy human immunodeficiency virus (HIV) seropositive individuals and 20 normal controls to evaluate its usefulness as a surrogate marker to distinguish between full blown AIDS cases and HIV seropositive individuals. However, it had a poor predictive value in establishing a diagnosis of full blown AIDS in an individual patient. Further, the coefficient of correlation between CD4+ T-lymphocyte count and b₂M was low both in patients with full blown AIDS and HIV seropositive individuals.

INTRODUCTION

Human Immunodeficiency Virus (HIV) epidemic has taken deep roots in India ever since the first case was documented in a sex worker in Tamil Nadu (1). It is estimated that by the year 2000, India will have 5 million infected individuals. Stunning advances have been made in a short time spanning a decade regarding the pathogenesis of acquired immunodeficiency syndrome [AIDS]. It was recognized quite early that CD4+T-lymphocytes cells are the key targets (2) for the HIV virus and during the development of full blown AIDS a substantial reduction in the numbers of

CD4+T-lymphocytes is an essential component (3). Enumeration of CD4 + T-lymphocytes has therefore been adjudged the best prognostic marker for the development of full blown AIDS and has been used regularly to monitor therapeutic regimes (4). Subsequently, however, it was revealed that the viral load assay was the most sensitive documentation of viral replication (5). Even when peripheral CD4+T-lymphocyte count is normal, there is a substantial replication of the virus in the tissues and blood (6-8). The draw back of these tests are that they are expensive and not available for routine use. While CD4+T-lymphocyte estimation requires sophisti-

Correspondence : S. Sehgal, Department of Immunopathology, Postgraduate Institute of Medical Education and Research, Chandigarh 160 012.

cated and expensive instrument i.e., flowcytometer and antibodies, the cost of viral assay is prohibitive. Most of the Indian patients belong to poor socio-economic background and they cannot afford these expensive tests. Surrogate markers thus have an important role in assessing prognosis of HIV infected patients. Beta-2 microglobulin [β_2 M] is one such marker used in patients with HIV infection and AIDS.

β_2 M is a small polypeptide that forms invariant chain with HLA class-I molecule and is present on all nucleated cells (9). Small amounts of β_2 M occur in various body fluids (10). Increased [β_2 M] levels in serum have been found in patients with malignancies including multiple myeloma where it is the most powerful prognostic and therapeutic marker (11). β_2 M also reflects lymphoid activation, destruction and hence is indicative of HIV replication (12).

In the present study, we evaluated the usefulness of serum β_2 M estimation in Indian patients with HIV infection and AIDS. We have attempted to address the question whether serum β_2 M can be a reliable surrogate marker to diagnose full blown AIDS in patients with HIV infection.

MATERIAL AND METHODS

Cases reporting to the AIDS Surveillance Centre, Department of Postgraduate Institute of Medical Education and Research, Chandigarh were included in the study. The diagnosis of HIV infection was established by two different ELISA tests,

i.e., Recombigen (Cambridge Biotech, Ireland), Detect (Biochem Immunosystem Inc., Canada) and a rapid test (Cambridge Biotech, Ireland) or Immunocomb (Organics, Israel). If all the three tests were frankly positive, the case was designated as HIV positive. In case of even a minor discord, Western blot test was performed (Newlav Blot-I/II, Sanofi Diagnostics, Pasteur, France). Clinical diagnosis of AIDS was established in 34 patients by the CDC clinical criteria or a CD4+T-lymphocyte count less than 200/mm³. Twenty apparently healthy HIV-positive individuals and 20 healthy normal controls were also included in the study and subjected to similar investigations.

Serum β_2 M estimation

β_2 M was estimated using an enzyme immunoassay (United Biotech, Inc. USA) based on a sandwich enzyme-linked immunosorbent assay [ELISA] principle. Briefly, β_2 M kit employs microwell coated with anti- β_2 M antibodies. Patient sera diluted 1 : 1000 and standards were incubated in the microwell for 30 minutes at room temperature. After washing in phosphate buffer saline, 100 μ l of the enzyme conjugated second antibody was added and the plate was incubated for another 30 minutes at room temperature. After several washings, the colour was developed using tetramethyl benzidine. After 10 minutes of incubation, the reaction was stopped by adding 100 μ l of 1N H₂SO₄. The intensity of the colour was read at 450nm. This was quantitated by plotting standards vs O.D. on a double log graph paper according to the manufacturer's instructions.

Estimation of CD4+T-lymphocytes

In twenty randomly selected cases absolute CD4+T-lymphocyte count was measured in a Becton Dickinson flowcytometer using anti-CD4 + and anti-CD8+ antibodies and consort-30 programme. Briefly, 100 µl of EDTA blood was incubated with 20 µl of the Simulset reagent for 30 minutes. The mixture was subjected to red cell lysis using a 1 to 10 dilution of the lysing fluid (Becton Dickinson). After incubating for 10 minutes, the cells were washed thrice in phosphate buffer saline pH 7.2 and viewed in the flowcytometer. The percentage of CD4 + T-lymphocytes was enumerated and their absolute number was calculated from absolute number of total lymphocytes.

Statistical analysis : Unpaired 't' test was employed in different groups to evaluate significance of β_2 M and CD4 + T-lymphocyte count. Correlation coefficients (r) were computed between CD4 + T-lymphocyte count and serum β_2 M levels in patients with full blown AIDS

and apparently healthy, HIV-seropositive individuals.

RESULTS

The mean age of full blown AIDS cases (n=34) was 35 [SD 12] years. There were 25 males. The mean age of apparently healthy HIV-seropositive individuals (n=20) was 26.7 [SD 7.5] years. The mean serum β_2 M level in patients with full blown AIDS was 6.7 (SD 2.3) mg/ml. Considering a level of 7 µg/ml as the cutoff, 17 of the 34 patients with full blown AIDS (50%) had levels >7 µg/ml. Among the HIV-seropositive individuals the mean serum β_2 M level was 4.15 (SD 2.2) µg/ml. Two cases (10%) had levels >7 µg/ml. Mean serum β_2 M levels in 20 healthy controls was 1.7 (SD 3.5) µg/ml. These details are shown in Table 1 and Figure 1.

Considering 4.15 µg/ml, 26 cases [76.5%] of full blown AIDS and 9 HIV-seropositive individuals [45%] had values > 4.15 µg/ml. However, when the cut off was taken as the mean normal value in

Table 1 : Serum β_2 microglobulin levels in 30 patients with full blown AIDS, 20 HIV-seropositive individuals and 20 normal controls

Cutoff value (mg/ml)	AIDS n (%)	HIV-seropositive individuals n (%)	Normal controls n (%)
> 7.0	17 (50.0)	2 (10.0)	0 (0)
< 7.0	17 (50.0)	18 (90.0)	20 (100)
> 4.15	26 (76.5)	9 (45.0)	0 (0)
< 4.15	8 (23.5)	11 (55.0)	20 (100)
> 2.4	33 (97.6)	16 (80.0)	0 (0)
< 2.4	1 (2.9)	4 (20.0)	20 (100)




Figure 1. β_2 Microglobulin levels in control, HIV-positive individuals and AIDS patients.

controls \pm 2SD i.e., 2.4 $\mu\text{g}/\text{ml}$., then 33 patients with full blown AIDS (97%) and 16 seropositive (80%) had values above 2.4 mg/ml . Thus this cut off was not able to distinguish AIDS patients from HIV seropositive individuals.

The serum $\beta_2\text{M}$ values were significantly higher in patients with full blown AIDS compared to HIV-seropositive individuals ($p < 0.04$) and normal controls ($p < 0.001$). The serum $\beta_2\text{M}$ values in HIV seropositive individuals was significantly higher than that observed in normal control ($p < 0.001$). The sensitivity of $\beta_2\text{M}$ for diagnosis of full blown AIDS was 76.5% considering a $\text{CD4} + \text{T}$ -lymphocyte count of $200/\text{mm}^3$ as the gold standard and serum $\beta_2\text{M}$ level $> 4.15 \mu\text{g}/\text{ml}$ as a cutoff value.

There was no significant correlation between $\text{CD4} + \text{T}$ -lymphocyte count and

serum $\beta_2\text{M}$ in patients with full blown AIDS ($r = 0.16$) and HIV seropositive individuals ($r = 0.26$).

DISCUSSION

The time interval between HIV infection and full blown AIDS is variable ranging from 2-10 years, depending upon the route of infection, dose of the virus, institution of the type of therapy, nutritional factors of the host and presence or absence of coreceptors (3,6,7,14). Assessment of the stage of the disease is crucial for initiation of appropriate therapy. Since it is not possible to study the extent of viral replication repeatedly in India, lot of stress has been laid on $\text{CD4} + \text{T}$ -lymphocyte count and surrogate markers such as serum $\beta_2\text{M}$, p24 assays, neopterin levels etc (15). Assessing $\text{CD4} + \text{T}$ -lymphocyte count may be normal in the face of significant tissue viral replication

(7, 8). Therefore there is a need to have a set of adjunct markers which could be used to assess progression to AIDS as the cost of sequential viral load assay is prohibitive and will never be affordable.

In the present study there was a poor correlation between CD4 + T-lymphocyte count and β_2 M serum in both HIV-seropositive individuals and patients with full blown AIDS. Thus serum β_2 M levels cannot be used as a single marker to distinguish between full blown AIDS disease HIV-seropositivity.

In fact Fahey et al (16) also reiterated that although β_2 M levels followed

longitudinally had a strong predictive value, yet CD4+T-lymphocyte counts were the single most important parameters of activity (11). We conclude that although β_2 M is a useful surrogate marker to differentiate a group of patients with full blown AIDS from HIV-seropositive individuals without AIDS, yet it cannot be used interchangeably with absolute CD4+T-lymphocyte count and results in a given case should be interpreted with caution.

ACKNOWLEDGEMENT

The study was supported by the Department of Biotechnology, Government of India, New Delhi.

REFERENCES

1. Simoes EA, Babu PG, John TJ, Nirmala S, Solomon S, Lakshminarayana CS, and Quinn TC (1987). Evidence for HTLV-III infection in prostitutes in Tamil Nadu (India). *Indian J Med Res* 85 : 335-338.
2. Dalgleish AG, Beverlay PC, Chapham PR, Crawford DM, Greaves MF and Weiss RA (1984). The CD4 (T4) antigen in an essential component of the receptor for AIDS retrovirus. *Nature (London)* 312:763-767.
3. Fauci AS, Schnittman SM and G. (1993). NIH conference immunopathogenic mechanisms in HIV infection. *Ann Intern Med* 114:678-693.
4. Anderson RE, Lang W, Shikoski S, Royce R, Jewelb N and Winkelstein W (1990). Use of β_2 M and CD4 count to predict development of AIDS in persons with HIV infection. *Arch Intern Med* 150:73-77.
5. Mulder J, McKinney N, Christopherson C, Suinsky J, Greenfield L and Kwok S (1994). Rapid and simple PCR assay for quantitation of HIV-1 RNA in plasma: application to acute retroviral infection. *J Clin Microbiol* 32(2): 292-300.
6. Coffin JM (1995). HIV-I population dynamics in vivo: implications for genetic variation, pathogenesis and therapy. *Science* 267:483-489.
7. Ho DD, Neumann AU, Perelson AS, et al. (1995). Rapid turnover of plasma virions and CD4 lymphocytes in HIV-I infection. *Nature* 373:123-126.
8. Wei X, Ghosh SK, Taylor ME, et al (1995). Viral dynamics in human immunodeficiency virus type-I infection. *Nature* 373:117-122.
9. Cresswell P, Springer T, Stominger JL, Turner MJ, Grey HM and Kubo RT (1974). Immunological identity of the small subunit of HLA antigens and β_2 M

- and its turnover on the cell membrane. *Proc Nat Acad Sci [USA]* 71:2123-7.
10. Plesner T and Bjerrum OJ (1980). Distribution of "free" and HLA associated human β_2 M in some plasma membranes and biological fluids. *Scand J Immunol* 11:341-51.
 11. Bataille R, Grenier JJ, Sany J (1984). β_2 M in myeloma: optimal use for staging, prognosis and treatment - A prospective study of 160 patients. *Blood* 63 (2): 468-476.
 12. Fuchs D, Kramer A, Reibnegger et al (1991). Neopterin and β_2 M as prognostic indices in HIV infection. *Infection* 19 (suppl 2) : S98-S 102.
 13. CDC Surveillance case definition of AIDS. *MMWR* 41 No. RR17, 1993.
 14. Dragic T, Litwin V, Allway GP et al (1996). HIV-I entry into CD4+cells is mediated by the chemokine receptor CC-CKR-5. *Nature* 381:667-673.
 15. Bjerrum OW and Birgens HS (1986). Measurement of β_2 M in serum and plasma by ELISA. *Clinical Chemica Acta* 155: 69-76.
 16. Fahey JL, Taylor JMG, Detels R et al (1990). The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type-I. *N Engl J Med* 322 : 166-172.